Trial reportNeurology2025
Neuroimaging Markers Associated With Recurrent Stroke in Intracerebral Hemorrhage and Atrial Fibrillation: Secondary Analysis of PRESTIGE-AF.
Trial report in Neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03996772 (PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation (PRESTIGE-AF)
Who cites it
1 citing paper in PubMed.
- Disease Progression in Iatrogenic Cerebral Amyloid Angiopathy.Neurology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesAnticoagulation in patients with intracerebral hemorrhage (ICH) and atrial fibrillation reduces the risk of ischemic stroke (IS), but also potentially causes an excess risk of recurrent ICH. In this context, we assessed the role of neuroimaging in identifying patients with particular susceptibility to IS or ICH, potentially allowing for individualized risk stratification.
methodsIn PRESTIGE-AF, a prospective, randomized clinical trial conducted across 75 hospitals in 6 European countries, participants with spontaneous ICH and atrial fibrillation were randomized to treatment with direct oral anticoagulants or no anticoagulation. Within a prespecified imaging subanalysis, we centrally assessed brain CT and MRI scans at baseline using established scales and definitions. We performed Cox regression analyses to investigate associations of neuroimaging findings with recurrent ICH and IS.
resultsPRESTIGE-AF included 319 patients, and 313 had neuroimaging of sufficient quality (median age 79 years, 35.5% female). MRI was available in 170 patients (54.3%). During a median follow-up of 1.4 years, 13 patients had recurrent ICH and 22 patients had IS. ICH recurrence was not associated with lobar vs nonlobar hematoma location or the overall category of probable cerebral amyloid angiopathy ( DISCUSSION: Neuroimaging contributes to the identification of patients with ICH and atrial fibrillation at particularly high risk of recurrent ICH or IS, emphasizing its role in clinical decision making. MRI allows for the assessment of relevant neuroimaging markers that can aid the risk assessment in affected patients. Major study limitations include the modest number of outcome events, with confirmation of our findings needed in larger collaborations. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov NCT03996772; first submitted June 21, 2019; first patient enrolled: May 31, 2019; available at clinicaltrials.gov/study/NCT03996772.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.